SALMONELLA

VolverVolver

Resultados 67 resultados LastUpdate Última actualización 22/05/2022 [12:16:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 90 días / Applications published in the last 90 days



previousPage Página2 de 3 nextPage   por página


COMPANION DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIETARY INTERVENTIONS OR FAECAL MICROBIOTA TRANSPLANT

NºPublicación: US2022120747A1 21/04/2022

Solicitante:

GENETIC ANALYSIS AS [NO]

RU_2762266_C1

Resumen de: US2022120747A1

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet. In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet, especially to determine the likelihood that the dietary intervention may have a positive (i.e. beneficial) effect on the subject's GI tract, specifically the GI tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in GI tract samples, e.g. by nucleic acid analysis.

traducir

IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF

NºPublicación: CO2022003789A2 19/04/2022

Solicitante:

SERUM INSTITUTE OF INDIA PVT LTD [IN]

CA_3149972_A1

Resumen de: WO2021044436A2

The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella typhi and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.

traducir

Recombinant vector expressing multiple antigens in Eukaryote cytosol and an attenuated Salmonella Typhimurium as the vector delivery system to host cells

NºPublicación: KR20220048172A 19/04/2022

Solicitante:

전북대학교산학협력단

Resumen de: KR20220048172A

본 발명은 생체 치료 및 감염병 예방을 하기 위하여 셈리키 삼림열 바이러스(Semliki Forest Virus) RdRp, CMVp, SV40p, P2A를 이용하여 표지 단백질이 혁신적으로 증폭이 개선된 진핵 세포질 내 다중 항원을 발현하는 벡터 및 약독화된 능동적 살모넬라를 운반하기 위한 벡터 시스템을 확립하였으며, 본 발명의 다중 항원 발현용 재조합 벡터 및 이에 의해 형질전환된 살모넬라 티피뮤리움을 이용하면 생체 내 플라스미드 전달 및 표적 항원 발현이 효과적으로 이루어 질 수 있으므로 차세대 DNA 백신 기술로 유용하게 이용할 수 있다.

traducir

TREATMENT OF BENIGN NERVOUS SYSTEM TUMORS USING ATTENUATED SALMONELLA TYPHIMURIUM

NºPublicación: JP2022522350A 18/04/2022

Solicitante:

ザジェネラルホスピタルコーポレイション

US_2022125906_A1

Resumen de: WO2020176764A1

Compositions and methods for the treatment of benign nervous system tumors including schwannomas using attenuated Salmonella typhimurium and optionally one or more checkpoint inhibitors.

traducir

METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF

NºPublicación: EP3980057A1 13/04/2022

Solicitante:

INST CURIE [FR]
CENTRE NAT RECH SCIENT [FR]
INST NAT SANTE RECH MED [FR]
COMMISSARIAT ENERGIE ATOMIQUE [FR]
ASSIST PUBLIQUE HOPITAUX PARIS APHP [FR]
UNIV PARIS [FR]
UNIV UTAH RES FOUND [US]

WO_2020245321_A1

Resumen de: WO2020245321A1

The present invention relates to a method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods described herein are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

traducir

ANTIBODIES TARGETING A GALACTAN-BASED O-ANTIGEN OF K. PNEUMONIAE

NºPublicación: JP2022058341A 12/04/2022

Solicitante:

エックスフォー・ファーマシューティカルズ(オーストリア)ゲーエムべーハー

BR_112017017553_A2

Resumen de: WO2016131503A1

The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.

traducir

一种鞭毛素突变体及其在制备非洲猪瘟抗原融合蛋白中的应用

NºPublicación: CN114292314A 08/04/2022

Solicitante:

武汉科前生物股份有限公司华中农业大学

Resumen de: CN114292314A

本发明属于生物技术领域,公开了一种鞭毛素突变体及其在制备非洲猪瘟抗原融合蛋白中的应用。所述的鞭毛素突变体的氨基酸序列为SEQ ID NO.4所示。本发明提供的鞭毛素截短突变体Fm能够高效上清表达,每升摇瓶培养及纯化后的蛋白产率可以达到40mg,易于放大及规模化生产,可以提高鞭毛素蛋白的广泛应用。将其与非洲猪瘟抗原蛋白融合后,在保持鞭毛素佐剂活性的同时,提高重组抗原的可溶性及表达水平,大大降低了表达及纯化工艺成本。

traducir

GUT BACTERIA DERIVED MICROVESICLES FOR VACCINE DELIVERY

NºPublicación: US2022105168A1 07/04/2022

Solicitante:

QUADRAM INST BIOSCIENCE [GB]

WO_2020084295_A2

Resumen de: US2022105168A1

The present invention relates to a vaccine suitable for immunisation against influenza, plague or Y. pestis infection said vaccine comprising outer membrane vesicles (OMVs) and the plague vaccine including the V and/or F1 antigens of Y. pestis.

traducir

PROTECTION AGAINST STRESS-MEDIATED DAMAGE FROM IONIZING RADIATION

NºPublicación: US2022105155A1 07/04/2022

Solicitante:

CLEVELAND CLINIC FOUND [US]

US_2019381139_A1

Resumen de: US2022105155A1

The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries.

traducir

NEW IMMUNOGENIC COMPOSITIONS

NºPublicación: EP3976756A1 06/04/2022

Solicitante:

ETH ZUERICH [CH]

BR_112021023865_A2

Resumen de: EP3744828A1

The present invention relates to an immunogenic composition for Proteobacteria protection and reduced transmission. We have identified Proteobacteria strain combinations that generate an immune response capable of robustly driving bacterial enteropathogens into an evolutionary dead end and reducing the transmission of the bacterium. These inactivated immunogenic compositions and typically oral vaccines are easy to apply, cheap to produce, and can be stored long-term without cold-chain requirements making them ideal for application in livestock, or in resource-poor areas. They are believed to be the only immunogenic compositions and vaccine formulations capable of breaking the chain of transmission for these types of pathogen.

traducir

ANTIMICROBIAL AGENTS AGAINST SALMONELLA BACTERIA

NºPublicación: EP3978605A1 06/04/2022

Solicitante:

LYSANDO AG [LI]

Resumen de: EP3978605A1

The present invention relates to the field of antimicrobial agents active against Salmonella bacteria. In particular, the present invention relates to polypeptides comprising a first and a second amino acid sequence, wherein the first amino acid sequence is an endolysin, and wherein the second amino acid sequence is an antimicrobial peptide, cationic peptide, hydrophobic peptide, amphipathic peptide or sushi peptide, and wherein the polypeptide comprises at least one sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 and derivatives thereof. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to applications of the inventive polypeptides, nucleic acids, vectors, and/or host cells, in particular in the pharmaceutical field and in the field of food and feed.

traducir

ENGINEERED BINDING PROTEINS FOR RECOGNITION OF BACTERIA

NºPublicación: WO2022066842A1 31/03/2022

Solicitante:

MASSACHUSETTS INST TECHNOLOGY [US]

Resumen de: WO2022066842A1

Described herein are antigen-binding molecules that bind to bacteria (e.g., Listeria monocytogenes) and methods of use thereof. Also described herein are compositions and kits comprising these antigen-binding molecules.

traducir

A COMPOSITION FOR MUCOSAL ADMINISTRATION TO AVIANS

NºPublicación: KR20220041142A 31/03/2022

Solicitante:

PHIBRO ANIMAL HEALTH CORPORATION [US]

BR_112022000626_A2

Resumen de: WO2021021778A1

Inactivated antigens have only been used in avian medicine in parenterally administered vaccines. The only mucosally administered vaccines have been live, modified live, or attenuated vaccines. However, live vaccines have several disadvantages, including the risk of causing disease. Disclosed embodiments concern a composition comprising inactivated bacterial and/or viral antigens that is formulated for mucosal administration to an avian, and a method of using the composition. In certain embodiments, the composition comprises inactivated Clostridium perfringens type A antigens, and/or Salmonella spp. antigens, such as antigens from Salmonella kentucky, Salmonella typhimurium, and/or Salmonella enteriditis, or E. coli antigens. The composition may comprise a polyacrylic acid adjuvant. The composition may be administered to an avian in ovo, during the first 14 days after hatching, or after the first 14 days.

traducir

MODIFIED IMMUNE CELLS EXPRESSING FLAGELLIN POLYPEPTIDE

NºPublicación: US2022096547A1 31/03/2022

Solicitante:

NANJING LEGEND BIOTECH CO LTD [CN]

CN_113164578_A

Resumen de: US2022096547A1

Provided are modified immune cells expressing a flagellin polypeptide capable of binding to a toll-like receptor. The modified immune cell further comprises an engineered receptor. Also provided are methods and pharmaceutical compositions for cancer treatment using the modified immune cells.

traducir

Methods of increasing vaccine efficacy

NºPublicación: AU2020335893A1 31/03/2022

Solicitante:

GENOME PROTECTION INC

CN_114502573_A

Resumen de: AU2020335893A1

The present invention relates, in part, to compositions and methods for enhancement of an immune response and for increased vaccine efficacy by stimulation of the TLR5 receptor, for example, with a recombinant TLR5 agonist (

traducir

FAST AND PORTABLE MICROFLUIDIC DETECTION SYSTEM AS AN ALTERNATIVE TO SALMONELLA'S CLASSICAL CULTURE METHOD

NºPublicación: US2022098645A1 31/03/2022

Solicitante:

TUBITAK [TR]

WO_2020136595_PA

Resumen de: US2022098645A1

Every year, approximately 94 million cases of Salmonella gastroenteritis, with 155000 deaths, are reported each year and 85% of them reported to be food-borne. Investigation of the foods whether they are clean for Salmonella and sensitivity, easy applicability, absence of false positivity and negativity and the speed are the features sought in the analysis method for this investigation. It is not desirable for analysis to detect the presence of dead bacteria in food. Although the final product does not contain microbiologically harmful live bacteria during the food process, the detection of dead bacteria transmitted before the process causes the food product to be unfairly diagnosed as harmful. To prevent this situation, the analysis kits depending on molecular methods, increase their microorganism detection levels up to to 104 while reducing their sensitivity. Since the molecular methods cannot discriminate dead and live organisms, a confirmation test is required to prove that the positive result of the analysis belongs to the live bacteria in the food, which results in additional cost and time loss. In the same way, it is necessary to verify whether the colonies that grow in the gold standard culture method, belong to Salmonella bacteria. In the developed system; 105 dead bacterial DNA is eliminated in the food to prevent false positive results and the minimum detection limit is 10 bacteria. Also, in developed system, 4 primers specific to 6 regions of DNA are used. Therefo

traducir

РЕКОМБИНАНТНАЯ ПРОТИВОГРИППОЗНАЯ ВАКЦИНА С ШИРОКИМ СПЕКТРОМ ЗАЩИТЫ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ (ВЫДЕЛЕННАЯ ЗАЯВКА)

NºPublicación: RU2020134762A 29/03/2022

Solicitante:

федеральноегосударственноебюджетноеучреждениеНаучноисследовательскийинститутгриппаимААСмородинцеваМинистерстваздравоохраненияРоссийскойФедерации

Generic inert carrier escherichia coli and potential application thereof

NºPublicación: KR20220038687A 29/03/2022

Solicitante:

UNIV YANGZHOU [CN]

WO_2021232800_A1

Resumen de: CN111560341A

The invention discloses generic inert carrier salmonella S9H and a potential application thereof. The generic inert carrier salmonella S9H is obtained by continuously culturing inert carrier bacteriaS9 in vitro by using an LB solid and liquid culture medium for passage to the fortieth generation, under the condition of the quantity of bacteria with working concentration, the non-specific agglutination reaction with serum and whole blood of human sources, mouse sources, cattle sources, pig sources and poultry sources (including chickens, ducks, gooses, turkeys, pigeons and quails) can be avoided; due to the characteristics of carrying and surface expression displaying human sources, mouse sources, cattle sources, pig sources and poultry sources (including chickens, ducks, gooses, turkeys,pigeons and quails) for different resistance factors are realized, the generic inert carrier salmonella S9H can be applied to development of an indirect agglutination test detection method for simply,conveniently and quickly detecting human and various animal antigens or infected antibodies, improves and perfects the technical bottleneck of poor specificity and sensitivity of an existing agglutination test for agglutination antigen and antibody detection. The product has wide application value and market prospect.

traducir

Vaccine for livestock production systems

NºPublicación: NZ729153A 25/03/2022

Solicitante:

UNIV CALIFORNIA

US_2017267994_A1

Resumen de: NZ729153A

The invention relates to Salmonella enterica subsp. enterica strains that possess a mutation in the dam and a second mutation in at least one of sifA, spvB and mgtC that leads to loss of gene function. The combined loss of gene function provides an improved Salmonella vaccine.

traducir

Immunogenic compositions against enteric diseases and methods for its preparation thereof

NºPublicación: AU2020343943A1 24/03/2022

Solicitante:

SERUM INSTITUTE OF INDIA PVT LTD

CA_3149972_A1

Resumen de: AU2020343943A1

The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from

traducir

PREPARATION OF LIVE VACCINES

NºPublicación: US2022088168A1 24/03/2022

Solicitante:

ELANCO TIERGESUNDHEIT AG [US]

CN_112760252_A

Resumen de: US2022088168A1

Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.

traducir

A COMPOSITION FOR MUCOSAL ADMINISTRATION TO AVIANS

NºPublicación: CN114222584A 22/03/2022

Solicitante:

辉宝动物保健公司

KR_20220041142_PA

Resumen de: WO2021021778A1

Inactivated antigens have only been used in avian medicine in parenterally administered vaccines. The only mucosally administered vaccines have been live, modified live, or attenuated vaccines. However, live vaccines have several disadvantages, including the risk of causing disease. Disclosed embodiments concern a composition comprising inactivated bacterial and/or viral antigens that is formulated for mucosal administration to an avian, and a method of using the composition. In certain embodiments, the composition comprises inactivated Clostridium perfringens type A antigens, and/or Salmonella spp. antigens, such as antigens from Salmonella kentucky, Salmonella typhimurium, and/or Salmonella enteriditis, or E. coli antigens. The composition may comprise a polyacrylic acid adjuvant. The composition may be administered to an avian in ovo, during the first 14 days after hatching, or after the first 14 days.

traducir

Apparatus and method for detecting microbial contamination

NºPublicación: AU2022201210A1 17/03/2022

Solicitante:

EL DWEIK MAJED [US]

US_2020355682_A1

Resumen de: AU2022201210A1

Provided are novel methods for screening and testing for pathogens in food, water, and bodily fluids using methods that are faster to complete than conventional methods of culturing and plating that require lengthy times in properly equipped labs. The invention 5 utilizes specific, rapid and sensitive optical detection to capture small concentrations of the target bacteria and render them amenable for detection with various specific synthesis binding agents approaches. The technique merges capture and detection steps with quantification unit suitable to provide results in a relatively shorter time current detection methods.

traducir

RECOMBINANT LIVE VACCINE FOR SARS-COV-2 BASED ON RECOMBINANT SALMONELLA ENTERITIDIS

NºPublicación: WO2022055375A1 17/03/2022

Solicitante:

FARM VETERINARIOS SAC [PE]

PE_20201405_PA

Resumen de: WO2022055375A1

The present invention relates to a recombinant live vaccine based on a Salmonella enteritidis strain expressing the S protein of the Sars-2019-Cov-2 virus, wherein the best expression has been achieved when the insertion is in the plasmid rather than the chromosome. It also relates to a vaccine that requires such strain. Reference is also made to the use of a Salmonella enteritidis 3934 strain (deposited in the Spanish Type Culture Collection (CECT) under accession number CECT9332) for the treatment of SARS-Cov-2 and to the method for controlling the SARS-CoV-2 infection by administering a live recombinant vaccine to mammals.

traducir

RECOMBINANT SALMONELLA ENTERITIDIS AND USE THEREOF AS A VACCINE FOR PIGS

Nº publicación: AR120779A1 16/03/2022

Solicitante:

FARM VETERINARIOS S A C [PE]

PE_20211141_A1

Resumen de: WO2021125982A1

Attenuated, non-pathogenic strain of Salmonella enteritidis 3934Vac DwaaL of rough phenotype, modified to express the xenoantigen of the capsid protein (CAP) of porcine circovirus type 2 (PCV-2), and the method for obtaining said modified strain of Salmonella enteritidis. Also disclosed is a recombinant, effective and innocuous live anti-PCV-2 vaccine for pigs, developed using a process comprising the insertion and integration of the xenoantigen of the CAP of PCV-2 into the chromosome or plasmid of the attenuated, non-pathogenic strain of Salmonella enteritidis 3934Vac DwaaL.

traducir

previousPage Página2 de 3 nextPage por página

punteroimgVolver